AICAR
Published Research
PubMed-indexed studies for AICAR
AICAR, an AMPK activator, protects against cisplatin-induced acute kidney injury through the JAK/STAT/SOCS pathway.
View on PubMed →AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity.
View on PubMed →Lipophagy deficiency exacerbates ectopic lipid accumulation and tubular cells injury in diabetic nephropathy.
View on PubMed →AMPK activator AICAR in combination with anti-mouse IL10 mAb restores the functionality of intra-tumoral Tfh cells in the 4T1 mouse model.
View on PubMed →Prior treatment with the AMPK activator AICAR induces subsequently enhanced glucose uptake in isolated skeletal muscles from 24-month-old rats.
View on PubMed →AICAR attenuates ischemia-reperfusion-induced AKI by modulating AMPK-TXNIP-NLRP3 pathway and energy metabolism.
View on PubMed →Research-Grade AICAR
⚠️ For laboratory research only. Not for human use.

